Home » Stocks » RNA

Avidity Biosciences, Inc. (RNA)

Stock Price: $26.46 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 992.95M
Revenue (ttm) 6.09M
Net Income (ttm) n/a
Shares Out 37.42M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $26.46
Previous Close $26.46
Change ($) 0.00
Change (%) 0.00%
Day's Open 26.60
Day's Range 26.05 - 27.33
Day's Volume 289,125
52-Week Range 23.35 - 35.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

LA JOLLA, Calif., Dec. 22, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody O...

PRNewsWire - 4 weeks ago

LA JOLLA, Calif., Dec. 21, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody O...

Seeking Alpha - 1 month ago

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

Other stocks mentioned: ABNB, AI, AZEK, DASH, GBIO, PCVX, UCL, VRM
PRNewsWire - 2 months ago

LA JOLLA, Calif., Nov. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody O...

PRNewsWire - 3 months ago

LA JOLLA, Calif., Sept. 28, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody ...

PRNewsWire - 4 months ago

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, Aug. 10, 2020 /PRNewswire/ -- Avidity Biosciences, Inc.

PRNewsWire - 5 months ago

SAN DIEGO, July 27, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonuc...

CNN Business - 6 months ago

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...

Other stocks mentioned: BIO, FMTX, IMRA, KROS, PCVX, RPTX, XBI, ZNTL
PRNewsWire - 7 months ago

SAN DIEGO, June 16, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonuc...

Market Watch - 7 months ago

Shares of Avidity Biosciences Inc. RNA, +55.66% soared 50% in their trading debut on the Nasdaq on Friday after pricing at the top of their initial public offering range, a sign of heightened ...

Market Watch - 7 months ago

Avidity Biosciences Inc. RNA, , a biotech the specializes in treatments for muscular disorders, priced its initial public offering at $18 a share late Thursday, the high end of its price range.

PRNewsWire - 7 months ago

SAN DIEGO, June 11, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucl...

About RNA

Avidity Biosciences, a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and targe... [Read more...]

Industry
Biotechnology
IPO Date
Jun 12, 2020
Stock Exchange
NASDAQ
Ticker Symbol
RNA
Full Company Profile

Financial Performance

In 2019, RNA's revenue was $2.32 million, an increase of 511.87% compared to the previous year's $379,000. Losses were -$24.73 million, 120.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for RNA stock is "Strong Buy." The 12-month stock price forecast is 43.33, which is an increase of 63.76% from the latest price.

Price Target
$43.33
(63.76% upside)
Analyst Consensus: Strong Buy